ONCIMMUNE LEADING EARLY CANCER DETECTION
 
ONCIMMUNE LEADING EARLY CANCER DETECTION

EarlyCDT-Lung is not a molecular diagnostic test. It is an immunoassay and is relatively inexpensive

Oncimmune works with all insurance carriers and files claims to both Medicare and commercial insurance plans

  • As a Medicare provider, Oncimmune will file a claim for Medicare beneficiaries being tested to aid in the assessment of malignancy risk of indeterminate pulmonary nodules identified by a CT scan
  • If your health insurance company covers EarlyCDTLung, the cost of the test to the patient will be limited to co-pays, co-insurance and deductibles, as determined by the patient’s healthcare plan
  • If insurance coverage is denied, patients are encouraged to contact Oncimmune. We can help you
  • Oncimmune actively engages with all insurance companies to minimize the cost to each patient

The Oncimmune Patient Care Program enables patients to be tested even if they are denied insurance coverage or cannot afford the test

For more information about insurance and billing, please email clientservices@oncimmune.com or call 1-888-583-9030

  • Outside the US, EarlyCDT-Lung is currently self-pay

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept